The president secretary of Meikang Replied that the company’s COVID-19 antigen self-test products are self-developed products
Meikang Biological (300439) April 01 in the investor relations platform to answer the question of investor concern.Investor: Your company has been promoting the overseas market since last year, sometimes in The German market, sometimes in the Australian market, but there has been no progress in the market promotion till now.I would like to ask to what extent your company has actively promoted the overseas market. Please kindly reply to the secretary of the board seriously. Thank you.Chairman secretary of Meikang Bio: Dear investors!The company has applied for COVID-19 self-test product certification in Australia, and has applied for COVID-19 self-test product certification in Germany to be changed into COVID-19 professional product certification. Meanwhile, the company is preparing the application materials for THE US FDA EUA and domestic COVID-19 self-test product.The data preparation time and administrative approval time of the above products are uncertain. Investors are requested to invest rationally and pay attention to investment risks.Thank you for your attention!Investor: Hello, Director Secretary!During the COVID-19 emergency, your company’s stock price fell to a new low in the past month or so. Is there any unannounced negative factor in your company?Has your production been affected by the epidemic?Facing the current spread of omicron epidemic, are your products ready for production?Please let us know as soon as possible.Thank you very much!Chairman secretary of Meikang Bio: Dear investors!The company shall strictly comply with relevant laws and regulations and the relevant provisions and requirements of normative documents to fulfill its information disclosure obligations.At present, the company’s production and operation have not been affected by the epidemic.Thank you for your attention!Investor: Hello, Director Secretary!Do the company’s COVID-19 antigen self-test products fall into the category of COVID-19 rapid detection reagents?The conference called for tackling the core technology of COVID-19 fast detection reagent. Does the company have independent intellectual property rights for the core technology of self-testing products?Chairman secretary of Meikang Bio: Dear investors!The company’s COVID-19 antigen self-test products are self-developed products.The product data preparation time and administrative approval time of regulatory agencies are uncertain. Investors should invest rationally and pay attention to investment risks.Thank you for your attention!Investor: Hello, Director Secretary!How is the sales of your company’s COVID-19 test products this year?In addition, what is the progress of FDA certification application for your products in the United States?In addition, why has your company not applied for the sale of its COVID-19 antigen testing products in China?Could you please tell us the specific reasons and your next sales plan?Thank you very much!Chairman secretary of Meikang Bio: Dear investors!The company is preparing for the U.S. FDA EUA and domestic self-testing products for COVID-19 antigen.The product data preparation time and administrative approval time of regulatory agencies are uncertain. Investors should invest rationally and pay attention to investment risks.If the order amount reaches the disclosure standard, the Company will perform the information disclosure obligation in strict accordance with relevant laws and regulations and relevant provisions and requirements of normative documents.Thank you for your attention!Meikang biological 2021 quarterly report shows that the company’s main revenue of 1.721 billion yuan, a year-on-year decline of 1.62%;The mother’s net profit was 173 million yuan, down 42.35% year on year;Non-deduction net profit of 172 million yuan, up 30.99% year on year;In the third quarter of 2021, the company’s main business income in a single quarter was RMB 600 million, down 4.85% year on year.The net profit of the single quarter was 39.6047 million yuan, down 46.1% year on year;The net profit deducted from non-profits in a single quarter was 41.2672 million yuan, down 37.65% year-on-year;Debt ratio 34.32%, investment income 1.3248 million yuan, financial expenses 18.8918 million yuan, gross profit margin 40.92%.The stock has no agency rating in the last 90 days.Securities star valuation analysis tools show that Meikang Biology (300439) good company rating of 2.5 stars, good price rating of 1.5 stars, valuation composite rating of 2 stars.(Rating range: 1 ~ 5 stars, maximum 5 stars) Main business: in vitro diagnostic products research and development, production and sales, and provide third-party medical diagnostic services.The chairman of the board is Zou Bingde.Mr Zou Bingde: born in 1971, vice-chairman of party members, the Chinese nationality, no permanent residence abroad, a master’s degree, senior economist, senior engineer, graduated from zhejiang university school of medicine, preventive medicine, obtained in Canberra, Australia university master’s degree in business administration (MBA) and cheung kong graduate school of senior management staff master of business administration (EMBA) to learnpositionHe founded Meikang Co., Ltd. in July 2003 and has served successively as the chairman and general manager of the company. He has served as the chairman of the company since January 2016.A national health industry medical test industry branch, vice President of association of business management, member of the standing committee of the 6th council of China medical equipment association, China association of mark immune analysis professional committee of the standing committee, the clinical laboratory management in colleges and universities teaching material, the Chinese medical association “the international journal of laboratory medicine staff, a series of clinical inspection equipment of large works the reagent andConsumables, deputy editor volume classification, the 12th session of Chinese people’s political consultative conference committee, zhejiang province, zhejiang province medical equipment industry association, vice chairman, zhejiang social do medical association vice President, zheshang big health committee vice chairman, health industry research branch of ningbo, ningbo city, zhejiang province 15th session of the standing committee of the Chinese people’s political consultative conference (CPPCC), ningbo, chairman of the in vitro diagnostic industry alliance, ningbo medical equipment industry associationVice president, Vice president of Ningbo Pharmaceutical Association, standing Committee of the 18th People’s Congress of Yinzhou District, Ningbo, etc.Successively won the ten outstanding youth award for ningbo yinzhou area, ningbo yinzhou district “WuSiQing year” award, building a modern international port city of ningbo outstanding contributions advanced individual, yinzhou district the third outstanding builder of the socialist cause with Chinese characteristics, private entrepreneurs in zhejiang province science and technology innovation award, the national advanced individual in vitro diagnostic industry award for outstanding contribution expert, ningbo city, in politicsZheng Advanced individual, Ningbo Science and technology Innovation Special Award, Ningbo city “combination of knowledge and action, charming Ningbo businessman”, Zhejiang Province science and technology Progress Award third prize, Ningbo city science and technology progress first prize, science and technology new Zhejiang businessman and other honors.The above content is compiled by Securities Star according to public information, if you have any questions, please contact us.